Lysoway secures $3.4m to advance promising oral drug for Parkinson’s

Lysoway Therapeutics has received an additional research grant from The Michael J. Fox Foundation for Parkinson’s Research to advance its TMEM175 agonist program. The award, made through MJFF’s Parkinson’s Disease Therapeutics Pipeline Program, provides approximately $3.4 million to support preclini…